Article
"Value" Decision by NICE Met With Disapproval
Both, the scientific community and a charitable organization, Prostate Cancer UK, have criticized the drug approval body for not offering abiraterone to sufferers until after chemotherapy.
The decision not to offer a life-extending drug to prostate cancer sufferers until after they have received chemotherapy is a "kick in the teeth" for patients, a charity has said.
Prostate Cancer UK said the drug could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
The charity said the National Institute for Health and Care Excellence's (Nice) decision was unjust.
Scientists have also expressed their disappointment over the health watchdog's guidance not to recommend the drug in this circumstance. Experts from the Institute of Cancer Research (ICR) said there was clear evidence abiraterone was beneficial for patients before they underwent chemotherapy.
In final draft guidance, Nice said that the drug should not be widely used in the NHS in England to treat prostate cancer patients whose cancer has spread and who have previously received another type of hormone therapy before they are given chemotherapy.
Read the report here: http://bit.ly/1t5K7Gc
Source: The Guardian
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
